HomeTriptans

Triptans

Check Triptans Interactions →
51 interactions on record

Triptans has 51 known drug interactions based on U.S. FDA drug labeling data. Of these, 8 are contraindicated combinations that should be avoided entirely. 34 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Almotriptan Malate, Dihydroergotamine Mesylate, Frovatriptan Succinate. Patients taking Triptans should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total
51
Contraindicated
8
Major
34
Moderate
9

Contraindicated (8)

  • Triptans + Almotriptan MalateConcomitant use of other 5-HT1 agonists (triptans) within 24 hours of almotriptan malate is contraindicated.
  • Triptans + Dihydroergotamine MesylateSerotonin 5-HT1B/1D receptor agonists; additive coronary artery vasospasm risk; do not use within 24 hours of each other
  • Triptans + Frovatriptan SuccinateOther 5-HT1B/1D agonists have additive vasospastic effects with frovatriptan. Co-administration within 24 hours of each
  • Triptans + NaratriptanOther 5-HT1B/1D agonists (triptans) contraindicated within 24 hours of naratriptan due to risk of additive vasospastic r
  • Triptans + SumatriptanOther 5-HT1 agonists (triptans) have additive vasospastic effects with sumatriptan. Coadministration within 24 hours of
  • Triptans + Sumatriptan SuccinateOther 5-HT1 agonists (triptans) have additive vasospastic effects; contraindicated within 24 hours of sumatriptan succin
  • Triptans + Sumatriptan Succinate And Naproxen SodiumOther 5-HT1 agonists can cause vasospastic effects. Coadministration within 24 hours is contraindicated due to additive
  • Triptans + ZolmitriptanOther 5-HT1B/1D agonists including triptans contraindicated within 24 hours due to risk of additive vasospastic reaction

Major (34)

Moderate (9)

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.